Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, has revealed that it has dosed its first patient in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumour-specific anti-epidermal growth factor receptor (EGR) antibody-drug conjugate (ADC), it was reported yesterday.

The multicentre, dose-expansion, Phase 2a trial (AVID100-01; NCT03094169) will assess the efficacy, safety, and tolerability of AVID100 in patients with advanced, EGFR-overexpressing, TNBC (IHC 2+/3+). This is the third cohort launched and follows the earlier announced cohorts assessing AVID100 in patients with advanced squamous non-small cell lung cancer (sqNSCLC) and squamous cell carcinoma of the head and neck (SCCHN). In total, around 100 patients will be assessed across three EGFR-overexpressing tumour types: sqNSCLC, SCCHN, and TNBC.

AVID100 is a highly potent EGFR-targeting antibody-drug conjugate designed to achieve improved anti-tumour efficacy without a corresponding increase in toxicity against skin and other EGFR-expressing normal tissues. In preclinical studies, the product indicated significant anti-cancer activity in EGFR-overexpressing tumour models resistant to marketed EGFR inhibitors. AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development and targets both wild-type and mutant forms of EGFR.